. Author manuscript; available in PMC: 2012 Dec 27.

Published in final edited form as: Transplantation. 2011 Dec 27;92(12):1301–1308. doi: 10.1097/TP.0b013e318237d6d4

Table 1.

Donor Chimerism after Marrow and Subsequent Composite Tissue Grafts from DLA-Identical Littermates

Recipient #	Date of Marrow Graft	TBI Gy	Donor Marrow Cells × 10⁸ / kg	Post-Marrow Grafting Immuno-suppression	Date of Composite Tissue Allograft	% Donor Chimerism¹ (weeks)²		Post- Transplant Immuno-suppression	Graft Rejection	Weeks of follow-up³
Recipient #	Date of Marrow Graft	TBI Gy	Donor Marrow Cells × 10⁸ / kg	Post-Marrow Grafting Immuno-suppression	Date of Composite Tissue Allograft	Before	After	Post- Transplant Immuno-suppression	Graft Rejection	Weeks of follow-up³
G767	4/26/07	2	4.3	MMF/CSP	10/15/07	G62.3 (0) L37.5 (0)	G7.4 (35) L25.8 (35)	No	No	>90
G244	5/16/03	1	9.2	MMF/CSP	10/29/07	G62.5 (-1) L49.4 (-1)	G100 (31) L100 (31)	No	No	>77
G500	12/22/04	2	4.8	MMF/Rapa	12/18/07	G50.0 (-3) L66.0 (-3)	G36.1 (26) L42.4 (26)	No	No	>52
G969	12/13/07	2	4.1	MMF/CSP	4/14/08	G94.6 (-4) L49.5 (-4)	G100 (53) L100 (53)	No	No	>52
G949	1/4/08	1	2.8	MMF/CSP	10/27/08	G69.5 (0) L48.4 (0)	G38.3 (52) L45.3 (52)	No	No	>52

Data are presented as percent donor granulocytes (G) and lymphocytes (L).

Chimerism analyzed in weeks before or after composite tissue graft, week = 0.

Weeks of follow-up after composite tissue graft, week = 0.

G767 and G969 received 2 Gy TBI (day = 0) with postgrafting immunosuppression of MMF (10 mg/kg B.I.D. subq., days 0-27) and CSP (15 mg/kg B.I.D. orally , days -1-35) and received HCT on a protocol specifically for this study.

The following dogs received HCT under separate studies and were later transferred to the present study as mixed chimeras. G244 received 1 Gy TBI with postgrafting immunosuppression of MMF (10 mg/kg B.I.D subq., days 0-27) CSP (15 mg/kg B.I.D. orally, days -1-35) and methotrexate (0.4 mg/kg, I.V. days 1, 3, 6, 11).

G500 received 2 Gy TBI with postgrafting immunosuppression of MMF (10 mg/kg B.I.D subq., days 0-34) and sirolimus (0.05 mg/kg, daily, subq, day -5 to 25).

G949 received 1 Gy TBI on day = 0, recombinant canine CTLA4-Ig (4.0 mg/kg I.V. days -7 and -5) donor PBMC (1 × 10⁶ cells/kg on days -7 and -5 injected subq and I.V.) and post grafting immunosuppression consisting of MMF (10 mg/kg B.I.D. subq., days 0-27) and CSP (15 mg/kg B.I.D. orally , days -1-35).